Hormone Replacement Therapy Market

Global Hormone Replacement Therapy Market Snapshot

The global hormone replacement therapy market is estimated at USD 18.4 Billion in 2022 and is forecast to surpass USD 32.8 Billion by 2032, growing at a CAGR of 5.9% from 2022 to 2032.

The global hormone replacement therapy market is likely to create an absolute dollar opportunity of USD 14.4 Billion by the end of 2032. The global hormone replacement therapy market holds ~12% of the global therapy market.

Report Attributes	Details
Base Year Value (2021A)	USD 17.5 Billion
Estimated Year Value (2022E)	USD 18.4 Billion
Projected Year Value (2032F)	USD 32.8 Billion
Global Growth Rate (2022-2032)	CAGR 5.9%
North America Market Share in 2021	~27%
North America Growth Rate (2022-2032)	CAGR ~6.3%
Collective Value Share (US, China, India) 2022: Top 3 Countries	~43%
Top 5 Companies Market Share in 2021	~35%
Key Companies Profiled	Novo Nordisk A/S Pfizer Inc. Endo International Plc Allergen Plc Janssen NV Novartis AG Bayer AG Merck KGaA Mithra Pharmaceuticals Teva Pharmaceuticals Mylan N.V Other Market Players

2017-2021 Global Hormone Replacement Therapy Market Outlook in Comparison to 2022-2032 Growth Forecast

Hormone replacement therapy, also referred to as menopausal hormone therapy, is used to treat various symptoms related to menopause among women. Hormone replacement therapy replaces hormones that are low in level as women near menopause. There are various types of hormone replacement therapy such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy.

Food and Drug Administration (FDA) has signed an agreement with NASEM (National Academies of Science, Engineering & Medicine) and is carrying out expanded agreements with University of Maryland and Johns Hopkins University Centers for Regulatory Science and Innovation. Main focus behind this initiative was to conduct research and inform consumers regarding compounded drugs.

NASEM is examining the utility of treating individuals with compounded BHRT (Bioidentical Hormone Replacement Therapy) products. Compounded Bioidentical hormone replacement therapy products such as testosterone and progesterone are used instead of FDA approved hormone replacement therapy drugs as BHRT drugs are considered more safe and natural for patients. This factor is likely to impact the clinical trials of new hormone replacement therapy products in turn challenging the growth of hormone replacement therapy market.

Fact.MR projects the hormone replacement therapy market is expected to witness exhibiting growth at 5.9% CAGR during 2022 and 2032 in comparison to a CAGR of 4.1% with which it grew from 2017 and 2021.

Use of Low Cost Generic Versions of Hormone Replacement Therapy Drugs – An Upcoming Trend

Affordability has always remained a major challenge for any pharmaceutical drug or formulation. Moreover, insufficient healthcare reimbursements have resulted in individuals opting for cheaper drugs with unclear drug effectiveness. This prompted manufactures of hormone replacement therapy drugs to produce generic versions of the formulations in a bid to bridge the gap between purchasing power of people and hormone replacement therapy drug pricing.

Companies developing generic hormone replacement therapy drugs are also acquiring FDA approvals, which is direct inference apropos to drug effectiveness. For instance, Teva pharmaceuticals has introduced generic version of Estrace cream and estradiol vaginal cream in 2018. The trend is expected to auger well for the overall growth of the hormone replacement therapy market.

Rising Prevalence of Osteoporosis to Influence Hormone Replacement Therapy Demand

Growing life expectancy is closely associated with degeneration that further translates into osteoporotic fractures. In addition, this condition further results in an increase in gap between spine bones during menopause with diminishing estrogen levels. According to the International Osteoporosis Foundation, osteoporosis causes over 8.9 million fractures annually on the global front and is likely to grow in the coming years. Rising prevalence of osteoporosis among women is expected to trigger the demand for hormone replacement therapy.

Hormone Replacement Therapy Associated with Reduced Dementia – Key Growth Propellant

Hormone replacement therapy can protect memory which is required to carry out short-term cognitive tasks after menopausal stress. Estrogen-only hormone replacement therapy can facilitate lower stress levels without impacting memory. In addition, hormone replacement therapy also reduces possibilities of both vascular dementia and Alzheimer’s disease.

Combination Hormone Replacement Therapy Associated with Cancer – Key Growth Deterrent

Use of hormone replacement therapy can lead to cancerous cell development. The use of combination hormone replacement therapy (combination of progesterone and estrogen) can increase the risk of breast cancer by 75 percent even if used for a short timeframe.

According to the U.S Women’s Health Initiative, the use of combination hormone replacement therapy comes with the risk of development of several cancers including ovarian cancer and uterus cancers. This aspect is expected to confine the growth in adoption of hormone replacement therapy in the forthcoming years. Other hormone replacement therapy related disorders such as stroke, cardiac disorders and blood clots are further expected to negatively impact the growth of the hormone replacement therapy market.

Major companies in the hormone replacement therapy market are concentrating on expanding their current product portfolio. New hormone replacement therapy formulations being the core focus, companies are carrying out trials and gain FDA approvals. Private equity firms are focused on acquiring emerging participants that are involved in drug delivery systems in the hormone replacement therapy space.

Competitive Landscape: Top Companies in Hormone Replacement Therapy Market

The global hormone replacement therapy market is highly fragmented and competitive owing to the existence of many domestic and regional players. Various marketing strategies are adopted by key players such as mergers and acquisitions, expansions, collaborations and partnerships.

Also, new product development as a strategic approach is adopted by the leading companies to upscale their market presence among consumers. These strategies have resulted in the growth of hormone replacement therapy market.

Fact.MR has provided detailed information about price points of key manufacturers in hormone replacement therapy market positioned across regions, sales growth, production capacity, and speculative technological expansion in the recently published report.

For instance:

• Pfizer Inc. in 2022 completed the acquisition of Arena Pharmaceuticals. This acquisition will lead to enhancement in portfolio to dermatology, cardiology, gastroenterology etc.
• Allergen Plc was acquired by AbbVie in 2020. This acquisition is likely to expand the portfolio to oncology, immunology, neuroscience etc.

Global Hormone Replacement Therapy Market by Category

• By Product Type

  • Estrogen Hormone Replacement Therapy
  • Thyroid Replacement Therapy
  • Growth Hormone Replacement Therapy

• By Dosage Form

  • Tablets
  • Patches
  • Injections
  • Implants
  • Creams
  • Others

• By Indication

  • Menopause
  • Osteoporosis
  • Thyroid
  • Growth Hormone Deficiency

• By Sales Channel

  • Hospital Pharmacies
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies

• By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • MEA